
The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.
Dr Zhang, MD, discusses cognitive assessment data from patients with metastatic castrate-resistant prostate cancer in the ODENZA trial receiving either darolutamide or enzalutamide that was presented at the European Society for Medical Oncology 2021 Annual Meeting.
OncLive® Rapid Readout from European Society of Medical Oncology 2021: Results from ODENZA Trial
Segment Description:
Tian Zhang, MD, discusses data from the following presentation: “Objective Computerized Cognitive Assessment in Men With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Randomly Receiving Darolutamide or Enzalutamide in the ODENZA Trial.” (
Segment Body Content:




